Loading clinical trials...

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE3

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

NCT06113471•Incyte Corporation

View on ClinicalTrials.gov

Summary

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged ≥ 18 years.
•Clinical diagnosis of nonsegmental vitiligo and meet the following:
•* T-BSA ≥ 5%
•* T-VASI score ≥ 4
•* F-BSA ≥ 0.5%
•* F-VASI score ≥ 0.5
•Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
•Willingness to avoid pregnancy or fathering children.

Exclusion Criteria

•Other forms of vitiligo or skin depigmentation disorders.
•Clinically significant abnormal TSH or free T4 at screening.
•Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1.
•Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®.
•History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo.
•Spontaneous and significant repigmentation within 6 months prior to screening.
•Women who are pregnant, considering pregnancy, or breast feeding.
•Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
•Evidence of infection with TB, HBV, HCV or HIV.
•History of failure to JAK inhibitor treatment of any inflammatory disease.
+1 more criteria

Locations (86)

University of Alabama At Birmingham Hospital-Whitaker Clinic

Birmingham, Alabama, United States

C2 Research Center, Llc

Montgomery, Alabama, United States

First Oc Dermatology Research Inc

Fountain Valley, California, United States

Center For Dermatology Clinical Research, Inc

Fremont, California, United States

Marvel Clinical Research Llc

Huntington Beach, California, United States

Vitiligo & Pigmentation Institute of Southern California

Los Angeles, California, United States

Dermatology Research Associates

Los Angeles, California, United States

Clinical Trials Research Institute

Thousand Oaks, California, United States

Skin Care Research, Llc

Boca Raton, Florida, United States

Total Vein and Skin Llc

Boynton Beach, Florida, United States

Key Dates

Start Date

November 27, 2023

Primary Completion Date

March 17, 2026

Completion Date

March 16, 2027

Last Updated

February 3, 2026

Enrollment

450

ACTUAL participants

Conditions

NonSegmental Vitiligo

Interventions

Povorcitinib

DRUG

Placebo

DRUG

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

NCT07437560

NonSegmental VitiligoNonsegmental Vitiligo (Stable)

View study

COMPLETEDPHASE3

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526

Stable Nonsegmental VitiligoActive Nonsegmental Vitiligo

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions